Balanced news tone
News Sentiment
RAPP sentiment intelligence
Rapport Therapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
58
Balanced news tone
73 relevant articles
Price is moving more forcefully than the current news tone suggests.
81/100 classification confidence.
directly relevant articles
high-authority source matches
+7.1% over one week, +8.7% over four weeks, trend active, and materially above fair value.
Rapport Therapeutics CEO Ceesay Abraham sells $328,436 in stock By Investing.com
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
81/100 classification
One-week reaction
7.1%
Price confirming higher
Trend fit
Trend active
8.7% over four weeks
Fair value
85.2%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
24
Neutral
43
Negative
6
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Investing.com Canada
Direct company coverage
Rapport Therapeutics CEO Ceesay Abraham sells $328,436 in stock By Investing.com
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 20:26
- Source
- Investing.com Canada
Investing.com Canada
Direct company coverage
Form 4 Rapport Therapeutics Inc For: 15 July By Investing.com
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 20:25
- Source
- Investing.com Canada
Investing.com
Direct company coverage
Rapport Therapeutics CEO Ceesay Abraham sells $328,436 in stock
Rapport Therapeutics CEO Ceesay Abraham sold shares worth $328,436 on July 14, 2026, executed under a Rule 10b5-1 trading plan. Despite the sale, Abraham retains significant direct and indirect ownership in the company, which has seen a 188% return over the past year. Analyst fir
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 15 Jul 2026 20:50
- Source
- Investing.com
TradingView
Direct company coverage
Enterprise value to revenue forward of Rapport Therapeutics, Inc. – NASDAQ:RAPP
This article provides a financial snapshot for Rapport Therapeutics, Inc. (NASDAQ: RAPP), focusing on its enterprise value to revenue forward metric. It appears to be a stub or a data placeholder from TradingView, indicating that specific financial data for this metric might be d
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 19:12
- Source
- TradingView
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Motley Fool
Direct company coverage
What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jul 2026 23:53
- Source
- Motley Fool
Stock Traders Daily
Direct company coverage
Responsive Playbooks and the RAPP Inflection
This article analyzes Rapport Therapeutics Inc. (NASDAQ: RAPP), highlighting a strong overweight bias due to positive sentiment across all time horizons. It details a compelling 57.8:1 risk-reward setup targeting a 16.2% gain, along with three distinct AI-generated trading strate
- Tone
- Positive 75/100
- Event
- Market update
- Published
- 12 Jul 2026 21:24
- Source
- Stock Traders Daily
Quartr
Direct company coverage
Rapport Therapeutics (RAPP) Q1 2026 earnings summary
Rapport Therapeutics (RAPP) reported its Q1 2026 earnings, highlighting $20.0 million in collaboration revenue from a new license agreement for RAP-219 in Greater China. The company's net loss narrowed to $19.9 million, and its lead candidate RAP-219 showed positive Phase 2a resu
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 10 Jul 2026 20:10
- Source
- Quartr
Quartr
Direct company coverage
Rapport Therapeutics (RAPP) TD Cowen 45th Annual Healthcare Conference Summary
Rapport Therapeutics (RAPP) presented at the TD Cowen 45th Annual Healthcare Conference, highlighting its precision neuroscience focus with lead program RAP-219. This drug targets TARP gamma-8 for focal onset seizures, showing a favorable safety profile and ongoing Phase 2A trial
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 10 Jul 2026 15:10
- Source
- Quartr
Sahm
Direct company coverage
4x P B For Rapport Therapeutics (RAPP) After Russell Index Additions Looks Pricey
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jul 2026 07:00
- Source
- Sahm
Quartr
Direct company coverage
Rapport Therapeutics (RAPP) Stifel 2025 Healthcare Conference Summary
This article summarizes Rapport Therapeutics' (RAPP) presentation at the Stifel 2025 Healthcare Conference, highlighting its precision neuroscience approach and lead program, RAP-219. The program shows promise in epilepsy with robust efficacy and tolerability in phase 2 studies,
- Tone
- Positive 94/100
- Event
- Market update
- Published
- 03 Jul 2026 19:42
- Source
- Quartr
Simply Wall Street
Direct company coverage
How Broad Russell Index Additions At Rapport Therapeutics (RAPP) Have Changed Its Investment Story
Rapport Therapeutics (RAPP) was recently added to several Russell growth and small-cap indices, including the Russell 2000 Growth and Russell 3000 Growth. While this inclusion will improve institutional visibility and liquidity, it doesn't alter the core clinical, funding, or exe
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 03 Jul 2026 16:46
- Source
- Simply Wall Street
GuruFocus
Direct company coverage
Insider Sell: Cheryl Gault Sells 10,000 Shares of Rapport Therap
Cheryl Gault, COO of Rapport Therapeutics Inc's subsidiary, sold 10,000 shares of RAPP on June 30, 2026, reducing her holdings to 149,914 shares. This transaction is part of a larger trend of insider selling at Rapport Therapeutics, with 30 insider sells against 3 buys over the p
- Tone
- Negative 37/100
- Event
- Market update
- Published
- 02 Jul 2026 18:09
- Source
- GuruFocus
Stock Titan
Direct company coverage
Rapport Therapeutics (RAPP) COO sells 10,000 shares in pre-set 10b5-1 trades
Rapport Therapeutics' Chief Operating Officer, Cheryl Gault, sold 10,000 shares of common stock on June 30, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan at weighted average prices between approximately $40 and $43 per share, totaling around
- Tone
- Negative 30/100
- Event
- Market update
- Published
- 02 Jul 2026 17:40
- Source
- Stock Titan
Finviz
Direct company coverage
RAPP - Rapport Therapeutics Inc Short Interest
This article provides a detailed overview of Rapport Therapeutics Inc. (RAPP) financial data, stock performance, and short interest as of July 2nd. It includes key metrics such as market cap, income, sales, various ratios, EPS estimates, and insider/institutional ownership percen
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 02 Jul 2026 13:39
- Source
- Finviz
Stock Traders Daily
Direct company coverage
Understanding the Setup: (RAPP) and Scalable Risk
This article analyzes Rapport Therapeutics Inc. (NASDAQ: RAPP), highlighting strong sentiment across all time horizons supporting an overweight bias. It details an exceptional 57.5:1 risk-reward setup, targeting a 16.3% gain against 0.3% risk. The analysis includes three AI-gener
- Tone
- Positive 75/100
- Event
- Market update
- Published
- 01 Jul 2026 20:16
- Source
- Stock Traders Daily
Stock Titan
Direct company coverage
Rapport Therapeutics (RAPP) CEO sells 8,220 shares under Rule 10b5-1 plans
Rapport Therapeutics (RAPP) CEO Abraham Ceesay sold 8,220 shares of common stock on June 29, 2026, through pre-arranged Rule 10b5-1 trading plans. The shares were sold in two transactions at weighted average prices of $39.77 and $40.34 per share. Following these sales, Ceesay dir
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 20:09
- Source
- Stock Titan
Stock Titan
Direct company coverage
[144] Rapport Therapeutics, Inc. SEC Filing
This SEC filing ([144] Form 144) for Rapport Therapeutics, Inc. (RAPP) details a proposed sale of 10,000 shares of common stock with an aggregate market value of $403,900.00. The shares were acquired as founders' shares on September 5, 2024, and are to be sold through Morgan Stan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 07:39
- Source
- Stock Titan
Investing.com South Africa
Direct company coverage
Rapport Therapeutics stock hits all-time high at 42.36 USD By Investing.com
Rapport Therapeutics Inc. stock has reached an all-time high of $42.36, reflecting a significant 1-year increase of 266.84% and market capitalization of $1.93 billion. This milestone is supported by strong analyst confidence, with multiple firms reiterating "Buy" or "Outperform"
- Tone
- Positive 86/100
- Event
- Analyst action
- Published
- 01 Jul 2026 04:39
- Source
- Investing.com South Africa
Investing.com
Direct company coverage
Rapport Therapeutics stock hits all-time high at 42.36 USD
Rapport Therapeutics Inc.'s stock has reached an all-time high of $42.36, showcasing significant investor confidence with a 266.84% increase over the last year and a market capitalization of $1.93 billion. This rise is supported by multiple analyst upgrades and positive sentiment
- Tone
- Positive 91/100
- Event
- Analyst action
- Published
- 30 Jun 2026 11:48
- Source
- Investing.com
www.marketscreener.com
Direct company coverage
Rapport Therapeutics, Inc.(NasdaqGM:RAPP) added to Russell Microcap Growth Benchmark Index
Rapport Therapeutics, Inc. (NasdaqGM:RAPP) has been added to the Russell Microcap Growth Benchmark Index. This inclusion is part of several recent additions to various Russell indices, reflecting the company's growing presence in the market. The clinical-stage biotechnology compa
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 29 Jun 2026 13:10
- Source
- www.marketscreener.com
marketscreener.com
Direct company coverage
Rapport Therapeutics, Inc.(NasdaqGM: RAPP) added to Russell 2000 Growth Benchmark
Rapport Therapeutics, Inc. (NasdaqGM: RAPP) has been added to the Russell 2000 Growth Benchmark. The company, a clinical-stage biotechnology firm, focuses on developing precision small-molecule medicines for neurological and psychiatric disorders, utilizing its RAP technology pla
- Tone
- Positive 74/100
- Event
- Market update
- Published
- 29 Jun 2026 07:32
- Source
- marketscreener.com
marketscreener.com
Direct company coverage
Rapport Therapeutics, Inc.(NasdaqGM: RAPP) added to Russell 3000E Growth Benchmark
Rapport Therapeutics, Inc. (NasdaqGM: RAPP) has been added to the Russell 3000E Growth Benchmark. This news follows several other recent additions to various Russell indices, underscoring the company's growing market presence. Rapport Therapeutics is a clinical-stage biotechnolog
- Tone
- Positive 72/100
- Event
- Market update
- Published
- 29 Jun 2026 05:07
- Source
- marketscreener.com
TradingView
Direct company coverage
Rapport Therapeutics, Inc. Actuals & Estimates (NASDAQ:RAPP)
This article provides an overview of Rapport Therapeutics, Inc. (NASDAQ:RAPP) stock, including its current price, historical performance, and analyst forecasts. It also details financial actuals and estimates for the company, covering earnings, revenue, and market capitalization,
- Tone
- Positive 74/100
- Event
- Earnings
- Published
- 26 Jun 2026 06:39
- Source
- TradingView
TradingView
Direct company coverage
RAPP Forecast — Price Target — Prediction for 2027
This article provides a forecast for Rapport Therapeutics, Inc. (RAPP) stock, including price targets and analyst ratings. It details the company's current stock price, historical performance, market capitalization, and upcoming earnings report. The piece also addresses frequentl
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 25 Jun 2026 14:11
- Source
- TradingView
marketscreener.com
Direct company coverage
Leerink Partners Initiates Rapport Therapeutics at Outperform With $52 Price Target
Leerink Partners has initiated coverage on Rapport Therapeutics with an Outperform rating and a $52 price target. This announcement highlights positive analyst sentiment for the biotechnology company, which focuses on developing precision medicines for neurological and psychiatri
- Tone
- Positive 72/100
- Event
- Analyst action
- Published
- 24 Jun 2026 11:40
- Source
- marketscreener.com
TradingKey
Direct company coverage
Rapport Therapeutics Inc (RAPP) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Rapport Therapeutics Inc (RAPP), detailing its current stock price, market capitalization, and various technical indicators. It presents a summary of buy, sell, and neutral signals based on indicators like MACD, RSI, and moving averag
- Tone
- Positive 63/100
- Event
- Market update
- Published
- 24 Jun 2026 02:10
- Source
- TradingKey
Stock Traders Daily
Direct company coverage
The Technical Signals Behind (RAPP) That Institutions Follow
This article analyzes Rapport Therapeutics Inc. (NASDAQ: RAPP), highlighting positive near-term sentiment but potential mid-term weakness within a strong long-term context. It details institutional trading strategies including long, breakout, and short setups, with specific entry
- Tone
- Positive 70/100
- Event
- Market update
- Published
- 20 Jun 2026 19:04
- Source
- Stock Traders Daily
TradingKey
Direct company coverage
Rapport Therapeutics Inc (RAPP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Rapport Therapeutics Inc (RAPP), noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It lists the current stock price and market
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 19 Jun 2026 00:39
- Source
- TradingKey
TradingKey
Direct company coverage
Rapport Therapeutics Inc (RAPP) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Rapport Therapeutics Inc (RAPP) focusing on its dividend history and stock splits. It states that the company has not distributed any dividends over the past five years and has no recorded stock split events. The article also includes current
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 18 Jun 2026 22:39
- Source
- TradingKey